VEGF antagonist formulations suitable for intravitreal administration

VEGF antagonist formulations suitable for intravitreal administration

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagon...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FURFINE, Eric, Dix, Daniel, Frye, Kelly, Graham, Kenneth
Format: Patent
Sprache:eng ; hun
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator FURFINE, Eric
Dix, Daniel
Frye, Kelly
Graham, Kenneth
description Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4. A pre-filled syringe is provided which is suitable for intravitreal administration comprising a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HUE018715TT2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HUE018715TT2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HUE018715TT23</originalsourceid><addsrcrecordid>eNrjZHANc3V3U0jMK0lMz8_LLC5RSMsvyi3NSSzJzM8rViguzSxJTMpJBYkqZOaVFCWWZZYUpSbmKCSm5GaC1BeBVfIwsKYl5hSn8kJpbgZFN9cQZw_d1IL8-NTigsTk1LzUkniPUFcDQwtzQ9OQECNjYtQAAFSENKo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>VEGF antagonist formulations suitable for intravitreal administration</title><source>esp@cenet</source><creator>FURFINE, Eric ; Dix, Daniel ; Frye, Kelly ; Graham, Kenneth</creator><creatorcontrib>FURFINE, Eric ; Dix, Daniel ; Frye, Kelly ; Graham, Kenneth</creatorcontrib><description>Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4. A pre-filled syringe is provided which is suitable for intravitreal administration comprising a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist.</description><language>eng ; hun</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241028&amp;DB=EPODOC&amp;CC=HU&amp;NR=E018715T2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241028&amp;DB=EPODOC&amp;CC=HU&amp;NR=E018715T2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FURFINE, Eric</creatorcontrib><creatorcontrib>Dix, Daniel</creatorcontrib><creatorcontrib>Frye, Kelly</creatorcontrib><creatorcontrib>Graham, Kenneth</creatorcontrib><title>VEGF antagonist formulations suitable for intravitreal administration</title><description>Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4. A pre-filled syringe is provided which is suitable for intravitreal administration comprising a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHANc3V3U0jMK0lMz8_LLC5RSMsvyi3NSSzJzM8rViguzSxJTMpJBYkqZOaVFCWWZZYUpSbmKCSm5GaC1BeBVfIwsKYl5hSn8kJpbgZFN9cQZw_d1IL8-NTigsTk1LzUkniPUFcDQwtzQ9OQECNjYtQAAFSENKo</recordid><startdate>20241028</startdate><enddate>20241028</enddate><creator>FURFINE, Eric</creator><creator>Dix, Daniel</creator><creator>Frye, Kelly</creator><creator>Graham, Kenneth</creator><scope>EVB</scope></search><sort><creationdate>20241028</creationdate><title>VEGF antagonist formulations suitable for intravitreal administration</title><author>FURFINE, Eric ; Dix, Daniel ; Frye, Kelly ; Graham, Kenneth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HUE018715TT23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; hun</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>FURFINE, Eric</creatorcontrib><creatorcontrib>Dix, Daniel</creatorcontrib><creatorcontrib>Frye, Kelly</creatorcontrib><creatorcontrib>Graham, Kenneth</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FURFINE, Eric</au><au>Dix, Daniel</au><au>Frye, Kelly</au><au>Graham, Kenneth</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>VEGF antagonist formulations suitable for intravitreal administration</title><date>2024-10-28</date><risdate>2024</risdate><abstract>Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4. A pre-filled syringe is provided which is suitable for intravitreal administration comprising a stable ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; hun
recordid cdi_epo_espacenet_HUE018715TT2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title VEGF antagonist formulations suitable for intravitreal administration
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T10%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FURFINE,%20Eric&rft.date=2024-10-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHUE018715TT2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true